Literature DB >> 35706855

SARS-CoV-2 Testing in India: Please Mind the Gaps.

Kanchan Mukherjee1.   

Abstract

Entities:  

Year:  2022        PMID: 35706855      PMCID: PMC9188899          DOI: 10.4103/ijpvm.IJPVM_472_20

Source DB:  PubMed          Journal:  Int J Prev Med        ISSN: 2008-7802


× No keyword cloud information.
This letter shares insights into the pandemic data situation in India based on a longitudinal study of SARS-CoV-2 testing rates and policy. In the initial phase of the pandemic (which included a 68-day national lockdown period), the testing policy was entirely based on reverse transcriptase–polymerase chain reaction (RT–PCR) (gold standard). However, during the unlock phase, on June 23, 2020, a rapid antigen test (RAT) with a moderate field sensitivity (50%–60%) was approved for testing. The lockdown period curtailed all non-essential movement of people, whereas subsequent unlock phases allowed movement based on the local situation. However, the virus had already spread before the lockdown started[1] and hence fast, effective testing was critical for the test-isolate-track/treat strategy for infection prevention. Analysis of the testing speed over 1 year shows a 287 times increase in testing rate in the initial 90 days after lockdown was initiated, followed by a steep and steady decline over time after the introduction of RAT in the unlock phase [Figure 1].
Figure 1

Testing speed in equal blocks of time (90 days)

Testing speed in equal blocks of time (90 days) Given the moderate sensitivity of RAT, the testing protocol[2] mandated an RT–PCR test for all symptomatic negative RAT cases to avoid false negatives. Since, the RAT is faster and requires fewer resources, numerous states and union territories have switched to this mode of testing. However, compliance with conducting RT–PCR to rule out false negatives has been low, with six densely populated states reporting less than 50% use of RT–PCR. Hence, virus-infected false negative RAT individuals are being excluded from the case management protocol and are contributing to the spread of COVID-19. These implications are confirmed by the second national serosurveillance study which reports the spread of virus to rural areas and estimates 26–32 infections for every COVID-19 case reported in India.[3] The slow testing speed and improper implementation of testing protocol using inaccurate RAT are critical gaps in India's response to the pandemic, which need to be urgently addressed. There are solutions available such as locally innovated, fast, accurate, and cost-effective diagnostic tests,[4] but the testing policy to date has not incorporated these scientific developments and evidences. These gaps between science, policy, and its implementation are affecting the accuracy of SARS-CoV-2 data in India, which has implications for national and global surveillance, international travel policies, and management of this pandemic. Hence, there is an urgent need to address these gaps in the interest of ensuring global health security.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  2 in total

1.  COVID-19 and lockdown: Insights from Mumbai.

Authors:  Kanchan Mukherjee
Journal:  Indian J Public Health       Date:  2020-06

2.  SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.

Authors:  Manoj V Murhekar; Tarun Bhatnagar; Sriram Selvaraju; V Saravanakumar; Jeromie Wesley Vivian Thangaraj; Naman Shah; Muthusamy Santhosh Kumar; Kiran Rade; R Sabarinathan; Smita Asthana; Rakesh Balachandar; Sampada Dipak Bangar; Avi Kumar Bansal; Jyothi Bhat; Vishal Chopra; Dasarathi Das; Alok Kumar Deb; Kangjam Rekha Devi; Gaurav Raj Dwivedi; S Muhammad Salim Khan; C P Girish Kumar; M Sunil Kumar; Avula Laxmaiah; Major Madhukar; Amarendra Mahapatra; Suman Sundar Mohanty; Chethana Rangaraju; Alka Turuk; Dinesh Kumar Baradwaj; Ashrafjit S Chahal; Falguni Debnath; Inaamul Haq; Arshad Kalliath; Srikanta Kanungo; Jaya Singh Kshatri; G G J Naga Lakshmi; Anindya Mitra; A R Nirmala; Ganta Venkata Prasad; Mariya Amin Qurieshi; Seema Sahay; Ramesh Kumar Sangwan; Krithikaa Sekar; Vijay Kumar Shukla; Prashant Kumar Singh; Pushpendra Singh; Rajeev Singh; Dantuluri Sheethal Varma; Ankit Viramgami; Samiran Panda; D C S Reddy; Balram Bhargava
Journal:  Lancet Glob Health       Date:  2021-01-27       Impact factor: 26.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.